Avid Bioservices Inc (CDMO)

[entdoc]

bottom line: PHM has established its capacity and know-how to produce a new product for which there is great demand. At this point they are merely "paying their dues" to join the club, amassing more evidence to prove over and over again the obvious. More unfortunate than stockholders are the patients dying earlier than necessary because of FDA rules promulgated to protect them, and because PPHM is under-financed and won't give any of its parts for a below market price. This is not the first exposure to market chicanery for any of us here, but probably one of the most painful. Anti-aminophospholipid MAB therapy is undoubtedly here to stay. Whether PPHM capitalizes on it remains to be seen. The odds still appear pretty good to me. The September anniversary of the PII labeling fiasco one year ago is a painful reminder of how expensive that event was for those holding PPHM stock, and those needing treatment with its product. Unbelievable, this.